Stéphane Bancel, CEO of Moderna, announced the development of a new mRNA shot to treat patients suffering from heart failure.

In a statement released on Monday, the pharmaceutical company said it currently has 48 programs in development, including 36 programs that are currently being tested in clinical trials.

These programs include mRNA infectious disease vaccines and mRNA therapeutics that span seven different modalities.

“We enter 2023 in a great position, with significant momentum across our clinical pipeline, a highly energized team and a strong balance sheet of over $18 billion of cash and cash equivalents,” said Stéphane Bancel, Chief Executive Officer of Moderna.


[link to www.thegatewaypundit.com (secure)]